Skip to content

Clinical trials

Leukemia, B-Cell trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Leukemia, B-Cell Country / region: China Clear all

43 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20152
20163
20176
20186
20195
20206
20212
20222
20231
20243
20254
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status26
Recruiting7
Withdrawn2
Not yet recruiting2
Completed2
Terminated2
Suspended1
Active, not recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Chongqing Precision Biotech Co., Ltd4
Chinese PLA General Hospital3
Nanfang Hospital, Southern Medical University3
Shenzhen Geno-Immune Medical Institute3
AstraZeneca2
Hebei Senlang Biotechnology Inc., Ltd.2
The First Affiliated Hospital with Nanjing Medical University2
iCell Gene Therapeutics2
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China1
Acerta Pharma BV1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Leukemia, B-Cell43
Lymphoma, B-Cell25
Leukemia9
Lymphoma7
Leukemia, Lymphocytic, Chronic, B-Cell6
Recurrence6
Burkitt Lymphoma2
Lymphoma, Mantle-Cell2
Lymphoma, Non-Hodgkin2
Precursor Cell Lymphoblastic Leukemia-Lymphoma2

Trials

Showing 76 to 43 of 43. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.